IDT Australia Ltd Asset Resilience Ratio
IDT Australia Ltd asset resilience ratio. IDT Australia Ltd (IDT) has an Asset Resilience Ratio of 9.76% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IDT defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of IDT Australia Ltd (2016–2025)
Asset resilience ratio of IDT Australia Ltd from 2016 to 2025. This chart shows how IDT Australia Ltd's Asset Resilience Ratio has changed over time. Read IDT current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down IDT Australia Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of IDT Australia Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$3.60 Million | 9.76% |
| Total Liquid Assets | AU$3.60 Million | 9.76% |
Asset Resilience Insights
- Limited Liquidity: IDT Australia Ltd maintains only 9.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
IDT Australia Ltd Industry Peers by Asset Resilience Ratio
Compare IDT Australia Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
IDT Australia Ltd Asset Resilience Ratio by Year (2016–2025)
IDT Australia Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for IDT Australia Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 9.76% | AU$3.60 Million ≈ $2.55 Million |
AU$36.92 Million ≈ $26.12 Million |
+8.48pp |
| 2024-06-30 | 1.28% | AU$400.00K ≈ $283.03K |
AU$31.37 Million ≈ $22.20 Million |
-- |
| 2017-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$58.12 Million ≈ $41.12 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$52.91 Million ≈ $37.44 Million |
-- |
About IDT Australia Ltd
IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States. The company offers microbiological and analytical testing, clinical packaging, and pharmacy services. It also provides medicinal cannabis and psychedelics; oral finished doses; and ase… Read more